CDKN2A and astrocytoma (excluding glioblastoma): For instance, preclinical evidence suggests that CDK4/6 inhibitors, already approved for use in breast cancer, exhibit antitumor effects on IDHm astrocytomas harboring a CDKN2A/B deletion [28].